bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-70-8501-01

Order Name:
ANA ( ANF ),  (IFA method)

 
Useful For:
Diagnosis of a systemic rheumatic disease in the suspected patient.
 
Methodology:
Indirect immunofluorescence assay
 
AliasesName:
ANA (Antinuclear Antibodies)
Antinuclear Antibodies (ANA), HEp-2 substrate, Serum
Antinuclear Antibody, Serum
FANA (fluorescent antinuclear antibodies)
ANA IFA
ANA IF
 
 
 
Test Code:
090-70-8501-01

Order Name:
ANA ( ANF ),  (IFA method)

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: N/A
Lipemia: N/A
Icterus: N/A
Other: Heat-treated specimen will be reject.
 
Specimen Stabillity:
Speciment Type Temperature Time
Serum Refrigerated, 2oC to 8oC 14 days
 
 
 
Test Code:
090-70-8501-01

Order Name:
ANA ( ANF ),  (IFA method)

 
Method detail:
Indirect immunofluorescence assay
 
Schedule:
Test daily, at 03:00 p.m.
 
Turnaround Time:
Received specimen to reported within 2 days.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
090-70-8501-01

Order Name:
ANA ( ANF ),  (IFA method)

 
 
Clinical Information:
The detection of antinuclear antibodies (ANAs) by indirect immunofluorescence are nowadays predominantly tested using for screening in the patients suspected of having an autoimmune disease, particularly of the rheumatic form.

Autoantibodies against nuclear antigens occur in many disease such as systemic lupus erythematosus (SLE), Sharp's syndrome, rheumatoid arthritis, progressive systemic sclerosis, polymyositis/dermatomyositis.  The diagnosis of a systemic rheumatic disease is based primarily on the presence of compatible clinical signs and symptoms. The results of tests for autoantibodies including ANA and specific autoantibodies are ancillary. Additional diagnostic criteria include consistent histopathology or specific radiographic findings.
 
Reference Value:
Negative
 
Interpretation:
The frequency (prevalence) of anti-nuclear antibodies in inflammatory rheumatic disease is between 20% and 100%, the lowest occuring in rheumatoid arthritis at between 20% and 40%. Therefore, differential antibody diagnostics against nuclear antigens is indispensible for the identification of individual rheumatic diseases and their differentiation from other autoimmune disease.  At times, antibodies against nuclear antigens are detectable in subjectively healthy individuals, usually at a low titer.  This finding is more common in women than men and the frequency of a detectable ANA in healthy women over 40 years of age may approach 15% to 20%. ANA may be detectable after viral illnesses, in chronic infections, or in patients treated with some kind of medications.  A diagnosis should not be made on a single test result. The clinical symptoms of the patient should alway be taken into account along with the serological results by the physician.  
 
Clinical Reference:
Manufacturer’s package insert, Mosaic HEp-20-10/Liver (Monkey) Instruction for the indirect immunofluorescencetest, January 2017, EUROIMMUN, D-23560 Lübeck Germany.